Gossamer Bio, Inc. (GOSS)

Profile

https://www.gossamerbio.com

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious cardiopulmonary and immune-mediated diseases. Its lead program is seralutinib, an investigational inhaled therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company also maintains a broader research pipeline that includes additional candidates across immunology, inflammation, and oncology, reflecting a focus on complex diseases with limited treatment options. Gossamer Bio works to advance its programs through clinical development and partnerships, positioning itself as a specialized biotechnology company centered on rare and chronic conditions. Headquartered in San Diego, California, Gossamer Bio serves as a development-stage player in the biopharmaceutical market.